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Objectives: Q fever is caused by Coxiella burnetii, an intracellular bacterium that infects phagocytes. The
aim of the present study was to investigate whether the C. burnetii-induced IFN-g response is defective in
chronic Q fever patients.
Methods: IFN-g was measured in supernatants of C. burnetii-stimulated peripheral blood mononuclear
cells (PBMCs) of 17 chronic Q fever patients and 17 healthy individuals. To assess IFN-g responses,
expression profiles of IFN-g-induced genes in C. burnetii-stimulated PBMCs were studied in six patients
and four healthy individuals. Neopterin was measured in PBMC supernatants (of eight patients and four
healthy individuals) and in sera (of 21 patients and 11 healthy individuals). In a genetic association study,
polymorphisms in genes involved in the Th1-cytokine response were analysed in a cohort of 139 chronic
Q fever patients and a cohort of 220 control individuals with previous exposition to C. burnetii.
Results: IFN-g production by C. burnetii-stimulated PBMCs from chronic Q fever patients was signifi-
cantly higher than in healthy controls. Many IFN-g response genes were strongly upregulated in PBMCs
of patients. Neopterin levels were significantly higher in PBMC supernatants and sera of patients. The
IL12B polymorphisms rs3212227 and rs2853694 were associated with chronic Q fever.
Conclusions: IFN-g production, as well as the response to IFN-g, is intact in chronic Q fever patients, and
even higher than in healthy individuals. Polymorphisms in the IL-12p40 gene are associated with chronic
Q fever. Thus, a deficiency in IFN-g responses does not explain the failure to clear the infection. The
genetic data suggest, however, that the IL-12/IFN-g pathway does play a role. T. Schoffelen, CMI
2017;23:209.e9e209.e15
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Q fever is a zoonosis caused by the bacterium Coxiella burnetii.
The infection is transmitted to humans by inhalation of aerosols
that contain bacteria from animal manure or birthing fluids [1].
Upon infection, over half of individuals remain asymptomatic,
while others develop acute Q fever [1]. Regardless of initialt of Internal Medicine and
iversity Medical Center, P.O.
(T. Schoffelen).
ivils de Lyon e bioMerieux,
biology and Infectious Diseases. Pumanifestations, a minority of individuals develop chronic infection
that may become apparent months or years after initial exposure.
Chronic Q fever mainly develops in people with pre-existing
valvular disease, aortic aneurysm, or vascular prostheses [2,3],
and may present as endocarditis, a mycotic aneurysm, or vascular
prosthesis infection. These are life-threatening conditions that
require long-term antibiotics and sometimes surgical intervention
[3]. During the 2007e2011 Q fever outbreak in the Netherlands, the
majority of patients with valvular/vascular risk factors for chronic Q
fever cleared the infection [4,5]; however, over 250 of these
developed chronic Q fever [6]. It is unknown what explains this
difference in susceptibility.
As an obligate intracellular pathogen, C. burnetii proliferates in
monocytes and macrophages, where it replicates in intracellularblished by Elsevier Ltd. All rights reserved.
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host's immune system requires a pro-inflammatory response with
granuloma formation and killing or control of the bacterium inside
activatedmonocytes/macrophages. The key cytokine in this process
is interferon-g (IFN-g), a pro-inflammatory cytokine, which acti-
vates macrophages, and stimulates immune cells to eliminate or
control intracellular pathogens. IFN-g production is induced by
type-1 cytokines secreted by monocytes/macrophages or dendritic
cells, most notably interleukin (IL)-12, IL-23, and IL-18.
The important role of IFN-g in the defence against C. burnetii is
supported by the high mortality observed in IFN-g-/- mice infected
with C. burnetii [8]. In vitro studies have also shown that IFN-g in-
duces killing of C. burnetii by monocytes, and inhibits growth of
C. burnetii in mouse fibroblasts [9e11]. It has been reported that
chronic Q fever is associated with a defective antigen-driven
lymphocyte proliferation to C. burnetii antigens, with intact re-
sponses to other antigens [12]. A substantial amount of C. burnetii-
specific IFN-g is produced by healthy individuals after vaccination
with killed C. burnetii and after natural infection [13]. Based on
these observations, it was assumed that chronic Q fever patients
have an inadequate IFN-g response to C. burnetii that leads to
persistent infection [8,10,14], but evidence for this hypothesis is
lacking. On the contrary, recent studies by us and others have
shown high antigen-specific IFN-g production in chronic Q fever
[15,16]. The aim of the present study is to investigate the IFN-g
response to C. burnetii in chronic Q fever patients.
Materials and methods
Ethics
The ethical committee of Radboud University Medical Center
(Nijmegen, the Netherlands) approved the study (NL35784.091.11).
Participants provided written informed consent (waiver when
deceased (n¼5), as approved by the ethical committee). Institu-
tional Review boards of participating hospitals approved the in-
clusion of participants in this study. The study was performed in
accordance with the Declaration of Helsinki.
Participants
For peripheral blood mononuclear cells (PBMCs) stimulations,
17 chronic Q fever patients, who visited the internal medicine
outpatient clinics of participating hospitals, were included
(Table S1). The diagnosis of chronic Q fever was based on the
publication of the Dutch chronic Q fever consensus group [17].
Seventeen healthy individuals without known history of Q fever,
were included as controls in these experiments.
For genetic analyses, all probable or proven chronic Q fever
patients [17], who visited the internal medicine outpatient clinics of
participating hospitals, were approached. They were recruited as
described before [18], and 139 patients were included. The at risk
control group consisted of 220 individuals from the same area with
vascular or valvular abnormalities predisposing to chronic Q fever,
with serological evidence of exposition to C. burnetii (anti-
C. burnetii phase II IgG antibodies 1:32) without clinical symp-
toms or serological evidence of chronic Q fever. These individuals
were recruited as described previously [18].
Bacteria
C. burnetii Nine Mile (NM) phase I (RSA 493) [19] and C. burnetii
3262 [20] were cultured at the Central Veterinary Institute (Lelys-
tad, the Netherlands), and the number of Coxiella DNA copies
determined, as described previously [21]. The C. burnetii strainswere inactivated by heating 30 minutes at 99C, and stored at
-80C. Q-vax vaccine (CSL Biotherapies, Victoria, Australia) [22]
contains formaldehyde-inactivated C. burnetii Henzerling strain
phase I in 50 mg/mL, and was used at 100 ng/mL.
PBMCs isolation and stimulation
PBMCs were isolated as previously described [23]. The PBMCs
[2.5  106/mL] were incubated in RPMI 1640 Dutch modification
culture medium (Sigma-Aldrich, St Louis, MO, USA) supplemented
with 1% L-glutamine, 1% pyruvate, and 1% gentamicin in a round-
bottomed 96-well plate (200 mL/well) at 37C and 5% CO2 with
heat-killed C. burnetii NM (107 bacteria/mL and 106 bacteria/mL),
heat-killed C. burnetii 3262 (106 bacteria/mL), Q-vax (100 ng/mL) or
heat-killed C. albicans (ATCC MYA-3573; UC820) (105 conidia/mL),
or culture medium alone. After 48 hours, supernatants were
collected and stored at 20C.
IFN-g and neopterin measurements
IFN-g production was measured in supernatants by enzyme-
linked immunosorbent assay (ELISA; Pelikine compact, Sanquin,
Amsterdam, the Netherlands). Neopterin was measured in super-
natants of eight patients and four healthy individuals and in sera
stored at -80C of 21 chronic Q fever patients and 11 healthy in-
dividuals by ELISA (IBL International, Hamburg, Germany).
Gene expression analysis
PBMCs (107 cells/mL) of six patients and four healthy individuals
were incubated for 8 hours in a flat-bottomed 24-well plate (1 mL/
well) at 37C and 5% CO2 with heat-killed C. burnetii NM (107
bacteria/mL), E. coli LPS (10 ng/mL) or culture medium alone. RNA
was extracted using the RNeasy Mini kit (Qiagen). RNA quality was
assessed using the 2100 Bioanalyzer and RNA 6000 Nano LabChip
kit (Agilent Technologies), and quantity was assessed using the
Nanodrop. Gene expression was analysed using Whole Human
Genome 4  44K microarrays (Agilent Technologies, Massy,
France), representing 45 000 probes and One-color Microarray
Based Gene Expression Analysis kit, as previously described [24].
The data were analysed with R and the Bioconductor software
suites. Raw data were preprocessed and quality-checked with
Agi4x44PreProcess library and normalized through quantile
normalization. Differential expression was assessed using Limma
library. Genes/probes were considered modulated if any stimula-
tion showed jFCj > 2 and corrected p <0.01.
To explore the IFN-g pathway activation, we performed func-
tional analysis based on Gene Ontology term GO:0034341
‘response to interferon-gamma’. We explored the activation of this
pathway by aggregating standardized (i.e. centre-reduced)
expression values within each gene-set of the modulated genes/
probes. Minimum Information About a Microarray Experiment
(MIAME)-compliant data were submitted to the Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) with acces-
sion number GSE66476.
Genotyping polymorphisms and determining associated IFN-g
response
From outpatient clinic patients, blood was drawn and stored at
-80C. DNA was isolated from these samples using standard
methods [25]. Other participants, both patients and control in-
dividuals, received a buccal swab kit (Isohelix, Cell Projects Ltd.,
Harrietsham, UK) to obtain epithelial cells. DNA was isolated using
a buccal DNA isolation kit (Isohelix). Single nucleotide
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effects on gene expression or protein function, published associa-
tions with human diseases, and/or haploview data. In total, nine
SNPs in IFNG, IFNGR1, IL18, IL12B, and IL12RB1were genotyped with
a Sequenom mass-spectrometry genotyping platform in July 2014.
Quality control was performed by duplicating 5% of the samples
within and across plates, by incorporating positive and negative
control samples and by sequencing samples to verify the various
genotypes.
In a subgroup of genotyped control individuals, whole blood
was stimulated with C. burnetii NM phase I (107 bacteria/mL) and
C. burnetii-induced IFN-g was measured, as described earlier [16].
Supernatants were stored at 20C.
Statistical analyses
Median IFN-g and neopterin concentrations were compared
using Mann-Whitney U tests, using GraphPad Prism (GraphPad
software Inc., version 5). Tests were two-sided and a p-value <0.05
was considered to be statistically significant.
Median standardized expression values of modulated genes
present in GO:0034341 were compared between patients and
healthy individuals and between stimulations using Wilcoxon
matched-pairs signed rank test. A p-value <0.001 (accounting for
multiple testing) was considered to be significant.
Hardy-Weinberg equilibrium (HWE) was analysed for all SNPs
in the control cohort [26]. Differences in genotype frequencies
between patients and controls were analysed by means of a gene
dosage model, with Fisher's exact test. Dominant and recessive
model analysis was performed by univariate logistic regression, for
which ORs and 95% CI are reported. Because the choice of genetic
variants was based exclusively on genes with an established role in
response to C. burnetii recognition, rather than exploratory, no
correction for multiple testing was performed. Statistical analyses
were carried out with IBM SPSS software (version 20).
Results
Intact C. burnetiieinduced IFN-g production by PBMCs of chronic Q
fever patients
The ability of PBMCs of chronic Q fever patients tomount a recall
response to C. burnetiiwas investigated by stimulation of PBMCs in
the absence of serum for 48 hours with various C. burnetii-strains
and subsequent measurement of IFN-g in the supernatants. High
IFN-g production was induced in PBMCs of 17 patients with allFig. 1. C. burnetii-induced IFN-g production is increased in chronic Q fever patients
compared with healthy individuals. IFN-g was measured in supernatants of PBMCs
stimulated for 48 hours with inactivated C. burnetii Nine Mile (106 bacteria/mL),
C. burnetii 3262 (106 bacteria/mL), C. burnetii Henzerling (100 ng/mL) (all phase I) and
Candida albicans (105 conidia/mL). Values are expressed as mean ± standard error. p-
Values are calculated using Mann-Whitney U test. **p <0.01, ***p <0.001.C. burnetii-strains and this was significantly different from the
response of 17 healthy individuals (Fig. 1). Interestingly, inactivated
C. albicans, known to induce IFN-g in PBMCs of healthy individuals,
led to significant less IFN-g production in chronic Q fever patients.
C. burnetii-induced upregulation of IFN-g response genes in chronic
Q fever patients
As chronic Q fever patients produce high amounts of IFN-g upon
C. burnetii stimulation, we wondered whether the pathway
downstream of IFN-g would be defective in chronic Q fever pa-
tients. In a whole-transcriptome analysis, the transcriptional re-
sponses of PBMCs to C. burnetii and, for comparison, to E. coli LPS
were investigated in six patients and four healthy controls.
The gene expression profiles overall showed a different activa-
tion pattern in unstimulated PBMCs of patients and healthy in-
dividuals compared with E. coli LPS or C. burnetii stimulated PBMCs.
PBMCs of patients stimulated with C. burnetii showed a very
distinct activation pattern (Fig. 2(a)). In the heat-map, the patients'
PBMCs stimulated with C. burnetii clustered together (Fig. 2(b)). We
focused our analysis on IFN-g response genes. First, we specifically
looked at genes that are described to be activated by IFN-g in
PBMCs and monocytes [27] (Table 1). We found that these were
mostly upregulated in C. burnetii-stimulated PBMCs of chronic Q
fever patients, in contrast to PBMCs of healthy individuals, while
E. coli LPS-stimulated PBMCs did not show a different expression
profile. Second, we assessed the transcriptional modulation of the
IFN-g response pathway (GO term GO:0034341 ‘response to
interferon-gamma’). One-hundred and fifty-one genes of
GO:0034341 were represented by probes in the microarray
(Table S2). Of these, 54 probes in 42 genes were modulated. The
median standardized expressions of the 54 probes, representing
the relative activation of the IFN-g response pathway, are shown in
Fig. 3. The highest activation of the IFN-g response was found in
C. burnetii-stimulated PBMCs of patients. Moreover, C. burnetii
stimulation showed a significantly higher activation in patients'
PBMCs compared with PBMCs of healthy individuals (p <0.001),
whereas there was no significant difference in activation on E. coli
LPS stimulation between patients and healthy individuals (p
>0.001).
Neopterin is increased in chronic Q fever
Neopterin is a highly stable molecule and its biosynthesis is seen
as a marker of activation of the cellular immune system, in
particular by IFN-g. In the course of a cellular immune reaction,
neopterin can be measured in serum. It is produced in vitro by
macrophages after stimulation with IFN-g. We found significantly
higher concentrations of neopterin in serum of 21 chronic Q fever
patients than in 11 healthy individuals (Fig. 4(a)). In addition, in the
supernatant of C. burnetii NM-stimulated PBMCs of chronic Q fever
patients, neopterin levels were significantly higher than those of
healthy individuals (Fig. 4(b)), while in supernatants of C. albicans-
stimulated PBMCs, neopterin concentrations were similar.
Polymorphisms in IL12B are associated with chronic Q fever and are
associated with decreased IFN-g production
We investigated whether subtle, common genetic variations in
the type-1 cytokine pathway, that affect IFN-g production or
response, are associated with the risk for development of chronic Q
fever. We performed a genetic association study using a cohort of
chronic Q fever patients and appropriate control individuals as
described previously [18]. In total, 139 (92 proven and 47 probable)
chronic Q fever patients and 220 control individuals without
Fig. 2. Distinct transcriptional profile of C. burnetii-stimulated PBMCs of chronic Q fever patients. PBMCs of six chronic Q fever patients (P) and four healthy volunteers (HV) were
either not stimulated (NS), or stimulated with heat-inactivated C. burnetii Nine Mile (107 bacteria/mL) (Cb), or stimulated with E. coli LPS (10 ng/mL) (LPS) for 8 hours. RNA was
extracted and a microarray was performed. (a) Graphical representation of the samples based on the correspondence analysis of the modulated probes. The samples are coloured
according to the group (patients versus healthy volunteers) and stimulus (not stimulated, C. burnetii or LPS). (b) Heatmap representation of the modulated probes in stimulated
PBMCs compared with unstimulated PBMCs. The probes are shown in the rows and the samples in the columns. The expression levels are colour-coded from blue to red. Below the
columns, samples are colour-coded as in A.
Table 1
Modulation of interferon-g related genes in PBMCs of chronic Q fever patients and healthy individuals stimulated by C. burnetii or E. coli LPS
Symbol HGNC Probe ID Stimulation with C. burnetii Stimulation with E. coli LPS
Chronic Q fever patients Healthy individuals Chronic Q fever patients Healthy individuals
BCL6 A_23_P57856 2.16 1.67 2.32 2.36
CD69 A_23_P87879 2.83 1.18 1.35 1.41
CISH A_24_P97465 3.19 1.02 1.08 1.23
CXCL9 A_23_P18452 62.5 0.45 1.24 4.53
CXCL10 A_24_P303091 16.5 0.20 0.64 1.67
CXCL11 A_23_P125278 15.5 0.10 0.70 1.45
GBP1 A_23_P62890 11.2 0.62 2.05 4.16
GBP2 A_23_P85693 2.75 0.88 1.31 1.97
HCAR3 A_23_P64721 5.35 2.42 2.59 2.47
ICAM1 A_23_P153320 6.66 3.09 3.87 3.65
IRF1 A_23_P41765 3.80 1.17 1.28 2.26
IRF8 A_23_P332190 3.16 0.72 1.09 1.36
RHOH A_23_P58132 2.39 0.84 1.23 1.11
RPS9 A_32_P223456 1.14 1.14 1.04 0.92
SERPING1 A_23_P139123 4.23 0.20 0.66 1.09
SOCS1 A_23_P420196 7.33 2.78 4.04 3.94
STAT1 A_24_P274270 2.00 0.54 1.29 2.21
UBE2L3 A_32_P100428 1.39 1.10 1.14 1.31
UBE3A A_24_P207150 1.10 1.06 0.89 1.06
VAMP5 A_23_P39840 2.43 0.68 0.89 1.21
PBMCs of six chronic Q fever patients and four healthy individuals were stimulated with heat-inactivated C. burnetii Nine Mile (107 bacteria/mL) or E. coli LPS (10 ng/mL) for
8 hours. The median ratios of gene expression in stimulated PBMCs to unstimulated PBMCs are shown. Listed genes are induced by interferon-g in PBMCs or monocytes, as
described by Waddell et al. [27]. HGNC, HUGO Gene Nomenclature Committee; ID, identification number.
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and a risk factor for chronic Q fever were included. Genotyping of
patients and controls was successful for all polymorphisms
(Table S3) in genes encoding IFN-g (IFNG), IFN-g receptor chain 1
(IFNGR1), IL-18 (IL18), IL-12p40 (IL12B), and the IL-12 receptor b1
chain (IL12RB1). For each polymorphism, >92% of the participants
were genotyped. All SNPs were in Hardy-Weinberg equilibrium in
the control group.
In the gene dosage analysis, genotyping revealed an association
between chronic Q fever and both IL12B polymorphisms: IL12B
rs2853694 (p 0.006) and IL12B rs3212227 (p 0.004). No associations
were observed between other polymorphisms and presence ofchronic Q fever (Table S4). Subsequently, IL12B rs2853694 was
found to be significantly differently distributed in a recessive model
analysis, leading to increased risk of chronic Q fever (p 0.001; OR
2.18, 95% CI 1.35e3.53). IL12B rs3212227 distribution was signifi-
cantly different in a dominantmodel analysis, with protective effect
of the C allele (p 0.004; OR 0.50, 95% CI 0.31e0.80) (Table S4). These
two polymorphisms are not strongly linked (r2¼0.248).
Next we investigated the functional consequences of these two
genetic variations by assessing the C. burnetii induced IFN-g pro-
duction in whole blood samples from control individuals stratified
for IL12B genotypes either in a recessive model (rs2853694; low-
risk AA/AC versus high-risk CC) or in a dominant model
Fig. 3. Chronic Q fever patients show increased relative activation of the ‘response to interferon-gamma’ pathway (Gene Ontology GO-term GO:0034341). PBMCs of four healthy
volunteers and six chronic Q fever patients were either not stimulated, stimulated with E. coli LPS (10 ng/mL), or stimulated with heat-inactivated C. burnetii Nine Mile (107 bacteria/
mL) for 8 hours. RNAwas extracted and a microarray was performed. The relative activation of the ‘response to interferon-gamma’ pathway was based on median standardized gene
expression of the 54 probes in the microarray that corresponded to 42 genes mapped in GO:0034341 and were significantly modulated in stimulated PBMCs (jFCj>2 and p <0.01)
(see Table S1 for a list of these 54 probes). The horizontal lines present the median, the boxes present the interquartile range (IQR), and the whiskers present 1.5*IQR. Outliers
(outside the whiskers) are plotted as dots. C. burnetii-stimulated PBMCs of patients showed significantly higher relative activation than those of healthy individuals (Wilcoxon test; p
<0.001), whereas there was no significant difference in relative activation on E. coli LPS stimulation between patients' and healthy individuals (p >0.001).
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mean C. burnetii-stimulated IFN-g production in individuals with
rs2853694 CC genotype (243 pg/mL) and AA/AC genotype (563 pg/
mL) was not significantly different (p 0.13). Individuals with
rs3212227 AC/CC low-risk genotypes and CC genotypes did not
show statistically different mean IFN-g production either (573 pg/
mL versus 428 pg/mL, p 0.40).
Discussion
We investigated the C. burnetii-induced IFN-g production and
response in chronic Q fever patients. We show that PBMCs of
chronic Q fever patients are not only capable of high IFN-g pro-
duction in response to C. burnetii in vitro, but also display upregu-
lation of IFN-g response genes and of the highly IFN-g-dependent
neopterin. In addition, we found in a large group of chronic Q fever
patients (n¼139) and control individuals that IL12B polymorphisms
are associated with progression to chronic Q fever.
Previously, it was assumed that chronic Q fever patients have an
inadequate T-cell derived IFN-g production in response to
C. burnetii infection. However, the current study could not confirm
this assumption. In contrast, our findings suggest that C. burnetii-
induced IFN-g production in chronic Q fever is increased. In a
previous study, Koster et al. [12] found that lymphocytes of chronic
Q fever patients fail to proliferate in vitro in response to C. burnetii
antigens. In one of these patients, this was demonstrated 5 years
after the endocarditis was treatedwith antibiotics and cardiac valve
replacement. This unresponsiveness was antigen-specific, as
lymphocyte proliferation in response to Candida antigens was
preserved [12]. Themethod of studying C. burnetii-specific adaptive
immune responses used by Koster et al., that is lymphocyte pro-
liferation, is different from our recent studies in which we showed
increased IFN-g production by ex vivo C. burnetii-stimulated whole
blood of chronic Q fever patients [28]. In our present study, we
confirmed these findings in PBMCs cultured for 48 hours in the
presence of three different C. burnetii strains. The absence ofautologous serum in these cultures shows that the IFN-g produc-
tion observed is not dependent on anti-C. burnetii antibodies.
Surprisingly, we found decreased IFN-g response to Candida
albicans in chronic Q fever patients compared with healthy in-
dividuals. This indicates that PBMCs of patients with an active
chronic Q fever infection are strongly responsive to C. burnetii in a
specific fashion, at the expense of responsiveness to other stimuli.
More research is necessary to validate this surprising finding and to
unravel the mechanism behind it.
Transcriptome analysis revealed that many IFN-g responsive
genes are upregulated in C. burnetii stimulated PBMCs of chronic Q
fever patients. In addition, IFN-g-dependent transcription factors
were specifically upregulated in C. burnetii stimulated PBMCs of
patients, and not in healthy individuals (data not shown). This
shows that the IFN-g signalling pathway is intact in chronic Q fever.
The high neopterin levels in vivodthe measurements in ser-
umdand in vitrodin C. burnetii-stimulated PBMCsdindicate that
macrophages of chronic Q fever patients are activated by IFN-g. This
confirms that the IFN-g signalling pathway is intact. In a previous
study, mean neopterin levels in plasma of 13 acute and 23 chronic Q
fever patients were also found to be increased (5.4 and 5.1 ng/mL,
respectively) compared with 17 healthy individuals (2.1 ng/mL),
although these differences were not significant [29].
Interestingly, our findings that the IFN-g pathway in response to
C. burnetii is intact in chronic Q fever patients can be added to the
observation that anti-C. burnetii antibody titres are high in chronic
Q fever patients [30]. Taken together, we conclude that we have not
found evidence for an impaired adaptive immune response in
chronic Q fever. As these patients are not able to kill the pathogen,
apparently the antibody response and the strong IFN-g response do
not lead to adequate bactericidal effects. Why these hosts fail to
eliminate the bacteria is still enigmatic.
IL-23 and IL-12 are critical in the innate immune response to
pathogens to induce production of IFN-g. An essential component
of both IL-23 and IL-12 is IL-12p40. In the present study, we found
that the presence of SNPs in the promoter (rs2853694) and at the
Fig. 4. C. burnetii-induced neopterin is significantly increased in chronic Q fever patients. (a) Neopterin was measured in serum of chronic Q fever patients (n¼21) and healthy
individuals (n¼11). (b) Neopterin was measured in supernatant of PBMCs of patients (n¼8) and of healthy individuals (n¼4) after stimulation for 48 hours with inactivated
C. burnetii Nine Mile (NM) phase I (107 bacteria/mL), C. burnetii NM phase I (106 bacteria/mL), and C. albicans (105 bacteria/mL). Medians of healthy individuals and patients are
compared by Mann-Whitney U test. ** p <0.01.
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the development of chronic Q fever. For both SNPs, associationwith
leprosy and tuberculosisdboth caused by Mycobacteria which are
also intracellular pathogensdhas been described [31e34]. For the
management of C. burnetii infection in patients at risk, these
polymorphisms may be incorporated in risk stratification for
development of chronic Q fever.
It might well be that the difference in IFN-g response to
C. burnetii in chronic Q fever patients is related to genetic poly-
morphisms in IL12B. However, we found that healthy individuals
with the risk genotype of the polymorphisms did not significantly
differ in in vitro IFN-g production on C. burnetii stimulation. Hence
wewere unable to prove that these polymorphisms have an impact
on the susceptibility to C. burnetii through production of IFN-g.
These polymorphisms may nevertheless have an effect in vivo on
production of IFN-g or other cytokines and on proliferation and
differentiation of various T cell subsets. The high IFN-g production
on C. burnetii stimulation in chronic Q fever patients is measured
during an active chronic infection and most likely results from an
ongoing stimulation of adaptive immune responses. In this light it
would be interesting to compare initial IFN-g responses between
acute Q fever patients who eventually develop a chronic infection
and thosewho do not. Honstettre et al. described a trend of reduced
IL-12p40 release by PBMCs during acute Q fever in patients withvalvulopathy, of whom 50% subsequently developed chronic Q fe-
ver [35].
There are some considerations that should be taken into account
when interpreting our results. First of all, we studied the immune
response of circulation blood cells to C. burnetii. Although difficult
to perform, it may be more relevant to study the local immune
response in C. burnetii-infected vascular walls or valvular tissue,
where these are mostly low-grade infections in which systemic
immune activation is apparently not effective in clearing the local
infection. The local immunological processes are likely to be crucial
for survival of C. burnetii at predilection sites such as defective
cardiac valves and aneurysmatic vascular wall. Immunohisto-
chemical studies of C. burnetii-infected cardiac valves showed
small, focal collections of infected mononuclear phagocytes [36].
Further identification of these cells and their immunological envi-
ronment could help us to understand the local persistence of
C. burnetii.
Second, the model that we used to study the IFN-g response to
C. burnetii, that is in vitro stimulation of PBMCs with heat-
inactivated bacteria, might not reflect the processes in vivo. In
particular, relatively high doses of C. burnetiiwere used to stimulate
the PBMCs in culture, comparedwith the low antigen load in serum
during Q fever infection.
T. Schoffelen et al. / Clinical Microbiology and Infection 23 (2017) 209.e9e209.e15 209.e15In conclusion, the present study shows that IFN-g production
and response to IFN-g are intact in chronic Q fever patients and do
not explain the failure to clear the infection. Our genetic analyses,
showing that IL12B polymorphisms are associated with chronic Q
fever, also points to the IFN-g pathway, although the functional
consequences of these polymorphisms in Q fever remain unclear.
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